ULTANE Liquid for inhalation Ref.[51168] Active ingredients: Sevoflurane

Source: FDA, National Drug Code (US)  Revision Year: 2022 

3. Indications and Usage

ULTANE is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

ULTANE should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane should be used.

10. Dosage and Administration

The concentration of sevoflurane being delivered from a vaporizer should be known. This may be accomplished by using a vaporizer calibrated specifically for sevoflurane. The administration of general anesthesia must be individualized based on the patient’s response.

Replacement of Desiccated CO2 Absorbents

When a clinician suspects that the CO2 absorbent may be desiccated, it should be replaced. The exothermic reaction that occurs with sevoflurane and CO2 absorbents is increased when the CO2 absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO2 absorbent canisters (see PRECAUTIONS).

Pre-anesthetic Medication

No specific premedication is either indicated or contraindicated with sevoflurane. The decision as to whether or not to premedicate and the choice of premedication is left to the discretion of the anesthesiologist.

Induction

Sevoflurane has a nonpungent odor and does not cause respiratory irritability; it is suitable for mask induction in pediatrics and adults.

Maintenance

Surgical levels of anesthesia can usually be achieved with concentrations of 0.5-3% sevoflurane with or without the concomitant use of nitrous oxide. Sevoflurane can be administered with any type of anesthesia circuit.

Table 9. MAC Values for Adults and Pediatric Patients According to Age:

Age of Patient (years) Sevoflurane in Oxygen Sevoflurane in
65% N2O/35% O2
0-1 months# 3.3%  
1 - <6 months 3.0%  
6 months - <3 years 2.8% 2.0% @
3-12 2.5%  
25 2.6% 1.4%
40 2.1% 1.1%
60 1.7% 0.9%
80 1.4% 0.7%

# Neonates are full-term gestational age. MAC in premature infants has not been determined.
@ In 1 - <3 year old pediatric patients, 60% N2O/40% O2 was used.

9. Overdosage

In the event of overdosage, or what may appear to be overdosage, the following action should be taken: discontinue administration of sevoflurane, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function.

14. Storage and Handling

Occupational Caution

There is no specific work exposure limit established for sevoflurane. However, the National Institute for Occupational Safety and Health has recommended an 8 hour time-weighted average limit of 2 ppm for halogenated anesthetic agents in general (0.5 ppm when coupled with exposure to N2O) (see ADVERSE REACTIONS).

Storage

Store at controlled room temperature, 15°-30°C (59°-86°F). See USP.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.